ACIU

AC Immune SA

3.50 USD
+0.02 (+0.57%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

AC Immune SA stock is down -14.43% since 30 days ago. The next earnings date is Aug 2, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 37.5% of the previous 7 July’s closed higher than June. In the last 1 Unusual Options Trades, there were 1 PUT.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
08 Jul 18:48 15 Nov, 2024 5.00 PUT 156 60

About AC Immune SA

AC Immune SA discovers, designs, and develops medicines and diagnostic products. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease. It is also developing ACI-24, an anti-Abeta vaccine candidate, as well as completed Phase Ib clinical study for Down syndrome. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases.